JY
BIO.B icon

Jeff Yass’s Bio-Rad Laboratories Class B BIO.B Stock Holding History

Jeff Yass’s Portfolio BIO.B Stock Details BIO.B Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-405
Closed -$200K – 13163
2022
Q2 		$200K Buy
+405
New +$216K ﹤0.01% 10628
2022
Q1 		– Sell
-496
Closed -$374K – 12982
2021
Q4 		$374K Buy
496
+44
+10% +$32.8K ﹤0.01% 9956
2021
Q3 		$336K Buy
452
+1
+0.2% +$754 ﹤0.01% 10329
2021
Q2 		$289K Sell
451
-1
-0.2% -$607 ﹤0.01% 10835
2021
Q1 		$257K Buy
+452
New +$269K ﹤0.01% 10931
2018
Q4 		– Sell
-1,555
Closed -$486K – 8935
2018
Q3 		$486K Buy
1,555
+92
+6% +$28.8K ﹤0.01% 6589
2018
Q2 		$420K Sell
1,463
-3
-0.2% -$826 ﹤0.01% 7151
2018
Q1 		$366K Buy
1,466
+436
+42% +$113K ﹤0.01% 7268
2017
Q4 		$246K Buy
1,030
+100
+11% +$24.1K ﹤0.01% 7909
2017
Q3 		$206K Buy
+930
New +$211K ﹤0.01% 7971

Other funds holding BIO.B

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
BSW
Buckingham Strategic Wealth Clayton, Missouri $9.66B AUM 15.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WT
Whittier Trust South Pasadena, California $10.2B AUM 33.39% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Jeff Yass's BIO.B Position: Q3 2022 in Review

Jeff Yass sold out of Bio-Rad Laboratories Class B (BIO.B) in Q3 2022, closing a stake of 405 shares — an estimated $200K sold.

Jeff Yass first reported a position in BIO.B in Q3 2017 and held it in 10 quarters. The position peaked at $486K in Q3 2018. 8 funds tracked by Wall St. Rank hold BIO.B as of Q3 2022.

  • Jeff Yass reported no remaining Bio-Rad Laboratories Class B position as of Q3 2022 after selling out during the quarter.
  • Jeff Yass sold 405 Bio-Rad Laboratories Class B shares in Q3 2022, an estimated $200K.
  • Jeff Yass first reported a position in Bio-Rad Laboratories Class B in Q3 2017 and held it in 10 quarters.
  • Jeff Yass's Bio-Rad Laboratories Class B position peaked at $486K in Q3 2018.
  • 8 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class B as of Q3 2022.

Based on Susquehanna International Group's 13F filing for Q3 2022, filed 14 Nov 2022.